MAGEC2
Melanoma-associated antigen C2
Protein Summary
Proposed to enhance ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases. In vitro enhances ubiquitin ligase activity of TRIM28 and stimulates p53/TP53 ubiquitination in presence of Ubl-conjugating enzyme UBE2H leading to p53/TP53 degradation. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzymes (E2) at the E3:substrate complex. This gene is a member of the MAGEC gene family. It is not expressed in normal tissues, except for testis, and is expressed in tumors of various histological types. This gene and the other MAGEC genes are clustered on chromosome Xq26-q27. [provided by RefSeq, Oct 2009]
- ENST00000247452
- ENSP00000354660
- ENSG00000046774
- HCA587
- MAGEE1
- CT10
- HCA587
- MAGEE1
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
microRNA | 0.57 | ||
biological term | 0.46 | ||
biological process | 0.42 | ||
cell line | 0.42 | ||
gene perturbation | 0.42 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 200.97 (req: < 5)
Gene RIFs: 32 (req: <= 3)
Antibodies: 141 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 200.97 (req: >= 5)
Gene RIFs: 32 (req: > 3)
Antibodies: 141 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 3
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0